Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$46.31
0.040.09%
At close: -
$46.32
0.010000.02%
After Hours: 4:01 PM EDT
Comments
Loading...
SpringWorks Therapeutics Analyst Ratings and Price Targets | NASDAQ:SWTX | Benzinga
SpringWorks Therapeutics Inc has a consensus price target of $55 based on the ratings of 9 analysts. The high is $77 issued by Wedbush on February 12, 2025. The low is $45 issued by B of A Securities on December 1, 2022. The 3 most-recent analyst ratings were released by Guggenheim, HC Wainwright & Co., and Guggenheim on May 12, 2025, April 30, 2025, and April 29, 2025, respectively. With an average price target of $47 between Guggenheim, HC Wainwright & Co., and Guggenheim, there's an implied 1.47% upside for SpringWorks Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
HC Wainwright & Co.
TD Cowen
Barclays
Wedbush
1calculated from analyst ratings
Analyst Ratings for SpringWorks Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/12/2025 | Buy Now | 1.47% | Guggenheim | Michael Schmidt55% | $47 → $47 | Reiterates | Neutral → Neutral | Get Alert |
| 04/30/2025 | Buy Now | 1.47% | HC Wainwright & Co. | Robert Burns42% | $74 → $47 | Downgrade | Buy → Neutral | Get Alert |
| 04/29/2025 | Buy Now | 1.47% | Guggenheim | Michael Schmidt55% | $77 → $47 | Downgrade | Buy → Neutral | Get Alert |
| 04/29/2025 | Buy Now | 1.47% | TD Cowen | Yaron Werber35% | $66 → $47 | Downgrade | Buy → Hold | Get Alert |
| 04/28/2025 | Buy Now | 1.47% | Barclays | Peter Lawson42% | $63 → $47 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 02/24/2025 | Buy Now | 59.76% | HC Wainwright & Co. | Robert Burns42% | $74 → $74 | Reiterates | Buy → Buy | Get Alert |
| 02/21/2025 | Buy Now | 59.76% | HC Wainwright & Co. | Robert Burns42% | $74 → $74 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2025 | Buy Now | 66.23% | Wedbush | David Nierengarten58% | $77 → $77 | Reiterates | Outperform → Outperform | Get Alert |
| 02/12/2025 | Buy Now | 40.33% | Evercore ISI Group | Cory Kasimov68% | $60 → $65 | Maintains | Outperform | Get Alert |
| 02/12/2025 | Buy Now | 59.76% | HC Wainwright & Co. | Robert Burns42% | $74 → $74 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2025 | Buy Now | 68.39% | Guggenheim | Michael Schmidt55% | $80 → $78 | Maintains | Buy | Get Alert |
| 11/20/2024 | Buy Now | 29.53% | Evercore ISI Group | Cory Kasimov68% | → $60 | Initiates | → Outperform | Get Alert |
| 11/12/2024 | Buy Now | 59.76% | HC Wainwright & Co. | Robert Burns42% | $76 → $74 | Maintains | Buy | Get Alert |
| 09/04/2024 | Buy Now | 46.8% | JP Morgan | Anupam Rama56% | $64 → $68 | Maintains | Overweight | Get Alert |
| 08/28/2024 | Buy Now | 64.08% | HC Wainwright & Co. | Robert Burns42% | $76 → $76 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | 59.76% | HC Wainwright & Co. | Robert Burns42% | $74 → $74 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2024 | Buy Now | 59.76% | HC Wainwright & Co. | Robert Burns42% | $74 → $74 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | 59.76% | HC Wainwright & Co. | Robert Burns42% | $74 → $74 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 61.92% | JP Morgan | Anupam Rama56% | $74 → $75 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 59.76% | HC Wainwright & Co. | Robert Burns42% | $73 → $74 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 36.01% | Barclays | Peter Lawson42% | $47 → $63 | Maintains | Overweight | Get Alert |
| 02/26/2024 | Buy Now | 51.12% | Wedbush | David Nierengarten58% | $60 → $70 | Maintains | Outperform | Get Alert |
| 01/25/2024 | Buy Now | 1.47% | Barclays | Peter Lawson42% | $41 → $47 | Maintains | Overweight | Get Alert |
| 11/29/2023 | Buy Now | 12.26% | Goldman Sachs | Corinne Jenkins47% | $47 → $52 | Maintains | Buy | Get Alert |
| 11/29/2023 | Buy Now | 57.6% | HC Wainwright & Co. | Robert Burns42% | $64 → $73 | Maintains | Buy | Get Alert |
| 11/28/2023 | Buy Now | 38.17% | HC Wainwright & Co. | Robert Burns42% | $52 → $64 | Maintains | Buy | Get Alert |
| 11/20/2023 | Buy Now | 12.26% | HC Wainwright & Co. | Robert Burns42% | $58 → $52 | Maintains | Buy | Get Alert |
| 11/09/2023 | Buy Now | 25.22% | HC Wainwright & Co. | Robert Burns42% | $66 → $58 | Maintains | Buy | Get Alert |
| 08/24/2023 | Buy Now | 42.49% | HC Wainwright & Co. | Robert Burns42% | → $66 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 42.49% | HC Wainwright & Co. | Robert Burns42% | $105 → $66 | Maintains | Buy | Get Alert |
| 07/20/2023 | Buy Now | 5.79% | Goldman Sachs | Corinne Jenkins47% | $43 → $49 | Maintains | Buy | Get Alert |
| 06/06/2023 | Buy Now | 126.68% | HC Wainwright & Co. | Robert Burns42% | → $105 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 126.68% | HC Wainwright & Co. | Robert Burns42% | → $105 | Reiterates | → Buy | Get Alert |
| 04/28/2023 | Buy Now | -11.49% | Barclays | Peter Lawson42% | $55 → $41 | Maintains | Overweight | Get Alert |
| 04/20/2023 | Buy Now | 126.68% | HC Wainwright & Co. | Robert Burns42% | → $105 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 23.06% | JP Morgan | Anupam Rama56% | $53 → $57 | Maintains | Overweight | Get Alert |
| 03/07/2023 | Buy Now | 126.68% | HC Wainwright & Co. | Robert Burns42% | $99 → $105 | Maintains | Buy | Get Alert |
| 01/26/2023 | Buy Now | -2.85% | Goldman Sachs | Corinne Jenkins47% | $40 → $45 | Maintains | Buy | Get Alert |
| 12/01/2022 | Buy Now | -2.85% | B of A Securities | Alec Stranahan33% | → $45 | Initiates | → Buy | Get Alert |
| 11/04/2022 | Buy Now | 113.73% | HC Wainwright & Co. | Robert Burns42% | $103 → $99 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | -5.01% | Goldman Sachs | Corinne Jenkins47% | $51 → $44 | Maintains | Buy | Get Alert |
| 09/12/2022 | Buy Now | 122.37% | HC Wainwright & Co. | Robert Burns42% | $94 → $103 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 102.94% | HC Wainwright & Co. | Robert Burns42% | $95 → $94 | Maintains | Buy | Get Alert |
| 06/06/2022 | Buy Now | 105.09% | HC Wainwright & Co. | Robert Burns42% | $142 → $95 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | 7.94% | Wedbush | David Nierengarten58% | $110 → $50 | Maintains | Outperform | Get Alert |
| 05/24/2022 | Buy Now | 77.03% | Goldman Sachs | Corinne Jenkins47% | $76 → $82 | Maintains | Buy | Get Alert |
FAQ
What is the target price for SpringWorks Therapeutics (SWTX) stock?
The latest price target for SpringWorks Therapeutics (NASDAQ:SWTX) was reported by Guggenheim on May 12, 2025. The analyst firm set a price target for $47.00 expecting SWTX to rise to within 12 months (a possible 1.47% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for SpringWorks Therapeutics (SWTX)?
The latest analyst rating for SpringWorks Therapeutics (NASDAQ:SWTX) was provided by Guggenheim, and SpringWorks Therapeutics reiterated their neutral rating.
When was the last upgrade for SpringWorks Therapeutics (SWTX)?
There is no last upgrade for SpringWorks Therapeutics
When was the last downgrade for SpringWorks Therapeutics (SWTX)?
The last downgrade for SpringWorks Therapeutics Inc happened on April 30, 2025 when HC Wainwright & Co. changed their price target from $74 to $47 for SpringWorks Therapeutics Inc.
When is the next analyst rating going to be posted or updated for SpringWorks Therapeutics (SWTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SpringWorks Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SpringWorks Therapeutics was filed on May 12, 2025 so you should expect the next rating to be made available sometime around May 12, 2026.
Is the Analyst Rating SpringWorks Therapeutics (SWTX) correct?
While ratings are subjective and will change, the latest SpringWorks Therapeutics (SWTX) rating was a reiterated with a price target of $47.00 to $47.00. The current price SpringWorks Therapeutics (SWTX) is trading at is $46.32, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
